Abstract 54P
Background
Brain tumors are the most common tumors causing dysfunctions and the most fatal types of cancers. Patients with Parkinson’s disease (PD), the second most common neurodegenerative disorders, may be at high risk for brain tumors due to synucleins expression, chronic neuro-inflammation, levodopa therapy and radiations, but there is still controversy especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the risk of brain tumors in patients with PD in South Korea.
Methods
We analyzed 52,009 patients diagnosed with PD between 2010 and 2015, and the age- and sex-matched 260,045 individuals without PD (mean age: 71.3 years; 40.8% men), using the data from the Korean National Health Insurance Database. Patients previously diagnosed with cancer were excluded. The cohorts were followed up to 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the association between PD and brain cancer.
Results
Patients with PD had a higher brain cancer risk (hazard ratio [HR], 1.73; 95% confidence interval [CI], 1.05–2.85) in female patients with PD than in those without PD after adjustment for multiple covariates. There was no significant difference in brain tumor incidence between the two cohorts in men (HR, 1.02; 95% CI, 0.52-2.02).
Conclusions
This nationwide population-based cohort study revealed that patients with PD had higher risk of brain tumors than those without PD in Korea. Further studies are required to determine the underlying mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract